Thermo Fisher Scientific Inc.
TMO
$609.82
+1.10%
Thermo Fisher Scientific is the world's largest provider of scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents, operating through four segments — analytical technologies (17% of sales), specialty diagnostics (11%), life science solutions (23%), and lab products & services including CRO work (the remainder) — serving pharmaceutical, biotech, clinical, academic, and industrial customers across roughly 125,000 employees globally. Its competitive identity rests on an unmatched scale-and-breadth platform: a razor-and-blade model where high-margin consumables and services (roughly 86% of segment revenue) create recurring, sticky revenue streams that few peers can replicate, positioning it as the sector's dominant 'picks-and-shovels' franchise. The current investor narrative centers on a return to mid-single-digit organic growth after the post-pandemic destocking trough, with Q1 2026 revenue up 6.2% year-over-year and management raising long-term guidance on the back of strong quarterly results, even as it flags 'modest inflation' risk tied to Middle East tensions. Debate now hinges on whether margin recovery and the accelerating CRO/biopharma services mix can sustain the re-rating the stock has enjoyed, or whether valuation has run ahead of fundamentals after a 24% one-year advance.…
TMO
Thermo Fisher Scientific Inc.
$609.82
Investment Opinion: Should I buy TMO Today?
Rating: Hold. TMO is a high-quality compounder with a dominant market position and recurring revenue, but the current valuation (32.6x trailing PE, 22.2x forward PE) already reflects much of the growth story. The analyst consensus is 'buy' with an average target of $645.15, implying only ~5.8% upside, which is modest relative to the risk. The stock has rallied 24% over the past year and 29.9% over three months, leaving limited margin of safety. We recommend holding existing positions but waiting for a better entry point before adding.
Supporting evidence: (1) Revenue grew 6.18% YoY in Q1 2026, with a favorable mix of 86% recurring consumables and services. (2) Net margin is a healthy 15.0%, and trailing FCF of $6.748B provides ample flexibility for buybacks and M&A. (3) The forward PE of 22.15x is a 32% discount to the trailing PE, implying expected EPS growth to $38.21, but the PEG of 4.54x suggests the growth is already priced in. (4) Analyst targets range from $520 to $750, with the average at $645.15, offering 5.8% upside. Compared to the broader healthcare sector, TMO's premium is justified by its quality, but the upside is limited.
Key risks that could invalidate the thesis: (1) Margin compression—gross margin fell to 40.67% in Q1 2026 from 41.83% in Q3 2025, and operating margin declined to 16.93% from 18.85% in Q4 2025. (2) Slower biopharma spending could reduce demand for CRO and life science solutions. (3) Valuation de-rating if growth disappoints; the stock could fall to the analyst low of $520 (-14.7%). The rating would upgrade to Buy if the stock pulls back to the $520-$550 range (forward PE ~14-15x) or if margins show sustained recovery above 18%. It would downgrade to Sell if revenue growth decelerates below 4% or if operating margins fall below 15%. Valuation verdict: fairly valued to slightly overvalued relative to history and peers, with the market pricing in continued execution.
Sign up to view all
TMO 12-Month Price Forecast
TMO is a high-quality franchise with a strong competitive moat, but the stock is fairly valued after a 24% one-year rally. The key tension is whether margin compression is transitory or structural; Q1 2026 operating margin of 16.93% was below Q4 2025's 18.85%, and management flagged inflation risks. While revenue growth is healthy at 6.18% YoY, the premium valuation (32.6x trailing PE, 4.54x PEG) leaves little room for error. We would upgrade to bullish if operating margins recover above 18% and revenue growth accelerates above 7%, or downgrade to bearish if margins fall below 15% or growth decelerates below 4%. The risk/reward is balanced, favoring a neutral stance until clearer margin trends emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $645.15 and implied upside of +5.8% versus the current price.
Average Target
$645.15
0 analysts
Implied Upside
+5.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
Coverage is broad and constructive, with 27 analysts covering TMO and a consensus recommendation of 'buy' (recommendation mean of 1.52, where 1.0 is a strong buy). The average price target of $645.15 implies roughly +5.8% upside from the current $609.82, a modest but positive expected return that reflects how much of the bull case is already priced in after the stock's 24% one-year run. Consensus revenue estimates of $58.78 billion and EPS estimates of $38.21 for the forward period underpin the target, and the bullish tilt is corroborated by recent institutional actions — Evercore ISI reiterating Outperform (July 2026), Wells Fargo maintaining Overweight (May 2026), and Barclays and Citigroup both staying constructive in early 2026. The one notable crack is HSBC's downgrade to Hold from Buy in June 2026, suggesting at least one house sees limited near-term upside after the rally. The target range is wide, from a low of $520.00 to a high of $750.00 — a spread of $230, or roughly 45% of the low target — which signals meaningful disagreement about the growth trajectory. The high target of $750 implies about 23% upside and likely assumes accelerating biopharma demand, margin recovery, and multiple expansion toward the upper end of TMO's historical band; the low target of $520 implies roughly 15% downside and likely prices in margin compression, tariff/inflation pressure, or a slower CRO recovery. The tight clustering of recent ratings around Buy/Outperform (with only HSBC moving to Hold) suggests the sell-side remains largely conviction-positive, but the wide target dispersion means investors should treat the consensus as a directional signal rather than a precise forecast.
Bulls vs Bears: TMO Investment Factors
The bull case rests on TMO's unmatched scale, recurring revenue mix, and re-accelerating growth, supported by a consensus buy rating and defensive beta. The bear case centers on a premium valuation (32.6x trailing PE, 4.54x PEG) that assumes continued margin recovery and earnings acceleration, leaving little room for error. Currently, the bull evidence is stronger: revenue growth is accelerating, profitability remains robust, and analyst sentiment is constructive. The single most important tension is whether margin compression—evidenced by the Q1 2026 operating margin decline to 16.93%—is transitory or structural. If margins recover, the premium multiple is justified; if not, the stock could de-rate sharply.
Bullish
- Recurring Revenue Dominance: Consumables ($4.722B) and services ($4.728B) together represent roughly 86% of segment revenue, creating a sticky, high-margin razor-and-blade model. This mix underpins revenue durability and supports the premium multiple.
- Accelerating Organic Growth: Q1 2026 revenue grew 6.18% YoY to $11.005B, with quarterly revenue climbing from $10.855B in Q2 2025 to $12.215B in Q4 2025. Management raised long-term guidance, signaling confidence in the re-acceleration.
- Strong Profitability and Cash Flow: Q1 2026 net income was $1.651B (15.0% net margin) with trailing FCF of $6.748B, an FCF yield of ~3.1%. ROE of 12.61% and ROA of 5.13% demonstrate efficient capital deployment.
- Analyst Consensus Buy with Upside: 27 analysts rate TMO a 'buy' (mean 1.52) with an average target of $645.15, implying ~5.8% upside. Recent reiterations from Evercore ISI, Wells Fargo, Barclays, and Citigroup reinforce positive sentiment.
Bearish
- Premium Valuation Leaves Little Room: Trailing PE of 32.61x and forward PE of 22.15x imply a 32% earnings growth expectation. PEG of 4.54x and EV/EBITDA of 21.58x are elevated, pricing in flawless execution.
- Margin Compression Risk: Gross margin fell to 40.67% in Q1 2026 from 41.83% in Q3 2025, and operating margin declined to 16.93% from 18.85% in Q4 2025. Management flagged 'modest inflation' from Middle East tensions.
- Aggressive Capital Allocation: Q1 2026 saw $8.872B in acquisitions and $3.0B in buybacks, funded partly by $4.215B debt repayment. Debt-to-equity of 0.737 and interest expense of $354M add financial risk.
- Wide Analyst Target Dispersion: Targets range from $520 to $750, a $230 spread (~45% of the low target). HSBC downgraded to Hold in June 2026, citing limited near-term upside after the 24% one-year rally.
TMO Technical Analysis
TMO is in a sustained uptrend, with the current price of $609.82 up 24.10% over the past year and sitting at roughly 82.5% of its 52-week range (low $435.27, high $647.00). That positioning — well above the midpoint but still about 5.7% below the 52-week high — signals a stock with strong momentum that has not yet become fully overextended, leaving room to test prior highs. The 31.32% six-month gain confirms the trend is durable rather than a brief spike, though the modest 2.92% YTD advance implies most of the move occurred in the back half of 2025 and early 2026. Recent momentum is positive but decelerating: the 1-month change of 1.13% and 3-month change of 29.93% show a sharp third-quarter surge followed by consolidation, and the 1-month figure lags the 3-month pace materially. Notably, TMO's 1-month relative strength versus SPY is +2.19 points (SPY -1.06% vs. TMO +1.13%), and its 3-month relative strength is a striking +26.89 points (SPY +3.04% vs. TMO +29.93%), confirming genuine market leadership — though the negative YTD relative strength of -9.16 points suggests the stock gave back early-year ground before reasserting itself. Key resistance sits at the 52-week high of $647.00, roughly 6.1% above the current price; a decisive breakout would signal a fresh leg higher, while support at the 52-week low of $435.27 (about 28.6% below) represents the deep downside reference, with intermediate support likely near the $570-$580 consolidation zone from July-August. With a beta of 0.854, TMO is roughly 15% less volatile than the broader market, making it a relatively defensive large-cap holding — a meaningful consideration for position sizing, as its drawdown risk is lower than the average S&P 500 constituent despite the stock's 31.45% max drawdown over the trailing period.
Beta
0.85
0.85x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$647
Price range past year
Annual Return
+24.1%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | -1.6% |
| 3m | +29.9% | +1.3% |
| 6m | +31.3% | +13.9% |
| 1y | +24.1% | +16.3% |
| ytd | +2.9% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue is growing at a healthy mid-single-digit clip: Q1 2026 revenue of $11.005 billion rose 6.18% year-over-year versus Q1 2025's $10.364 billion, and the multi-quarter trend is one of steady acceleration — quarterly revenue climbed from $10.855 billion (Q2 2025) to $11.122 billion (Q3 2025) to $12.215 billion (Q4 2025) before the seasonal Q1 step-down to $11.005 billion. The segment mix is favorable: consumables ($4.722 billion) and services ($4.728 billion) together dwarf instruments ($1.555 billion), meaning roughly 86% of reported segment revenue is recurring and higher-margin, which underpins revenue durability. This trajectory supports the investment case for a quality compounder re-accelerating off a cyclical trough, with the raised long-term guidance cited in April 2026 news reinforcing management's confidence. Profitability is robust and improving: Q1 2026 net income was $1.651 billion on a 15.0% net margin, with gross margin of 40.67% and operating margin of 16.93% — though gross margin compressed from 41.83% in Q3 2025 and 37.95% in Q4 2025, reflecting mix and cost dynamics. The company remains solidly profitable with a trailing ROE of 12.61% and ROA of 5.13%, and the Q1 2026 effective tax rate of just 4.0% flattered net income; the operating margin of 16.93% is below the 18.85% posted in Q4 2025, suggesting some near-term margin pressure that management attributes partly to 'modest inflation.' Balance sheet and cash flow metrics are solid but show leverage: debt-to-equity of 0.737 and a current ratio of 1.89 indicate adequate liquidity, while trailing free cash flow of $6.748 billion against a $217.9 billion market cap implies an FCF yield of roughly 3.1%. Q1 2026 operating cash flow of $1.192 billion funded $376 million of capex (FCF of $816 million) but was dwarfed by $8.872 billion of acquisitions and $3.0 billion of buybacks, funded partly by $4.215 billion of debt repayment activity — a reminder that TMO's capital allocation is aggressive and acquisition-driven, which supports growth but keeps financial risk moderate rather than minimal.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Because TMO is solidly profitable (Q1 2026 net income of $1.651 billion), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 32.61x versus a forward PE of 22.15x — a roughly 32% compression that implies the market expects meaningful earnings growth, consistent with consensus EPS estimates of $38.21 for the forward period versus the trailing figure. This wide trailing-to-forward gap signals that investors are underwriting an earnings acceleration, so any disappointment in that growth path would leave the multiple vulnerable. Relative to sector norms, TMO's 32.6x trailing PE and 4.89x PS sit at a premium to the broader healthcare sector, though the comparison is imperfect given TMO's premium quality and recurring-revenue mix; the EV/EBITDA of 21.58x and PEG of 4.54x suggest the market is paying up for growth that has yet to fully materialize. The 4.08x price-to-book and 27.87x price-to-cash-flow ratios further confirm a premium multiple structure typical of a high-quality, cash-generative franchise, and the 0.29% dividend yield with a low 9.4% payout ratio leaves ample room for continued buybacks and bolt-on M&A. Historically, TMO's PE has ranged from roughly 23.8x (Q2 2025) to 43.1x (Q1 2023), with the current 32.6x sitting in the middle-to-upper portion of that band — above the 27.1x-27.8x levels seen through much of 2025 but well below the 2023 peak. The current multiple therefore reflects optimism but is not at an extreme; the stock is priced for continued execution rather than perfection, leaving modest room for multiple expansion if growth accelerates, but also downside if margin compression persists.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but non-trivial. TMO carries debt-to-equity of 0.737 and a current ratio of 1.89, with Q1 2026 interest expense of $354 million. The company's aggressive M&A strategy—$8.872 billion in acquisitions in Q1 2026 alone—consumes cash and adds integration risk, while trailing free cash flow of $6.748 billion (3.1% yield) must cover both debt service and buybacks. Margin pressure is evident: gross margin fell to 40.67% in Q1 2026 from 41.83% in Q3 2025, and operating margin declined to 16.93% from 18.85% in Q4 2025. Management attributes this partly to 'modest inflation' from Middle East tensions, but if cost pressures persist, earnings growth could disappoint. Additionally, the Q1 2026 effective tax rate of just 4.0% flattered net income; a normalization would reduce profitability. Revenue concentration in life sciences and diagnostics exposes TMO to biopharma spending cycles, and any slowdown in CRO demand could disproportionately impact the lab products segment.
Market and competitive risks stem from TMO's premium valuation and cyclical end-markets. At 32.61x trailing PE and 21.58x EV/EBITDA, the stock trades at a premium to the broader healthcare sector, leaving it vulnerable to multiple compression if growth slows. The PEG ratio of 4.54x suggests the market is paying up for growth that has yet to fully materialize. With a beta of 0.854, TMO is less volatile than the market, but it is not immune to sector rotation—healthcare has underperformed in recent periods, and any shift toward value could pressure the multiple. Competition from Danaher, Agilent, and emerging Chinese players could erode pricing power, particularly in instruments. Regulatory risks, including potential drug pricing reforms and tariff exposure on imported lab equipment, add uncertainty. Recent news highlighting 'modest inflation' risk amid Middle East tensions underscores macro sensitivity, and the HSBC downgrade to Hold in June 2026 signals that some analysts see limited near-term upside.
The worst-case scenario involves a combination of margin compression, slower biopharma spending, and multiple de-rating. If operating margins fail to recover and forward EPS growth stalls, the stock could revert to the lower end of its historical PE band (~23.8x seen in Q2 2025). Applying 24x to forward EPS of $38.21 yields a price near $917—but that is above current levels, so the more relevant downside is the 52-week low of $435.27, which is 28.6% below the current price of $609.82. The analyst low target of $520 implies a 14.7% decline. A realistic bear case would see the stock test $520-$540, a loss of 11-15% from current levels, if margin pressure persists and growth decelerates. In a severe recession or biopharma funding freeze, the stock could approach the 52-week low, representing a ~29% drawdown.
FAQ
The most severe risk is margin compression: gross margin fell to 40.67% in Q1 2026 from 41.83% in Q3 2025, and operating margin declined to 16.93% from 18.85% in Q4 2025. If inflation persists, earnings could miss. Second, valuation risk: at 32.6x trailing PE and 4.54x PEG, the stock is vulnerable to de-rating if growth slows. Third, competitive risk: peers like Danaher and Agilent could pressure pricing, especially in instruments. Fourth, financial risk: debt-to-equity of 0.737 and $8.872B in Q1 2026 acquisitions increase integration and leverage risk. Finally, macro risk: Middle East tensions could disrupt supply chains and inflate costs, as management flagged 'modest inflation' risk. These risks are ranked from most to least severe, with margin compression being the most immediate threat.
Our 12-month forecast has three scenarios: Bull (25% probability) targets $700-$750, assuming accelerating biopharma demand and margin recovery; Base (55% probability) targets $620-$670, assuming mid-single-digit growth and stable margins; Bear (20% probability) targets $520-$560, assuming margin compression and slower spending. The base case is most likely, anchored by the analyst average target of $645.15 and forward EPS of $38.21. The key assumption is that operating margins stabilize around 17% and revenue grows 5-6%. If margins recover above 18%, the bull case gains traction; if they fall below 15%, the bear case becomes probable. The wide analyst target range ($520-$750) reflects significant uncertainty.
TMO appears fairly valued to slightly overvalued. The trailing PE of 32.61x is above the midpoint of its historical range (23.8x-43.1x), and the forward PE of 22.15x implies a 32% earnings growth expectation that may be optimistic given margin pressure. The PEG ratio of 4.54x is elevated, indicating the market is paying a premium for growth. Compared to the broader healthcare sector, TMO commands a premium due to its quality and recurring revenue mix, but the EV/EBITDA of 21.58x and PS of 4.89x are rich. The market is pricing in continued execution and margin recovery; any disappointment could lead to multiple compression. The stock is not undervalued, and the margin of safety is thin.
TMO is a high-quality company, but at $609.82, the risk/reward is balanced. The analyst average target of $645.15 implies only 5.8% upside, while the analyst low target of $520 represents 14.7% downside. The stock trades at a premium 32.6x trailing PE and 22.15x forward PE, with a PEG of 4.54x, suggesting growth is already priced in. For long-term investors, TMO offers a defensive way to play the life sciences tools sector, with recurring revenue and a strong moat. However, for new money, waiting for a pullback to the $550-$570 range would provide a better margin of safety. It is a good buy for patient investors with a 3-5 year horizon, but not a compelling short-term trade.
TMO is best suited for long-term investment. Its beta of 0.854 indicates lower volatility than the market, and its recurring revenue model (86% of segment revenue) provides earnings visibility. The dividend yield is modest at 0.29% with a low payout ratio of 9.4%, so income is not a primary draw. The stock has a 24% one-year return and a 31.45% max drawdown, suggesting it can be volatile in the short term. For short-term traders, the stock is consolidating after a sharp 3-month gain of 29.93%, with resistance at $647 and support at $570. A minimum holding period of 2-3 years is recommended to ride out cyclical fluctuations and benefit from long-term growth in biopharma spending. It is not suitable for those seeking quick gains or high dividends.